Identification
NamePuromycin
Accession NumberDB08437
TypeSmall Molecule
GroupsExperimental
Description

Puromycin is an antibiotic that is a protein synthesis inhibitor by inhibiting translation. Puromycin is used in cell biology as selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells.

Structure
Thumb
SynonymsNot Available
External IDs 3123-L / 3123L / CL-13900 / P-638
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII4A6ZS6Q2CL
CAS number53-79-2
WeightAverage: 471.5096
Monoisotopic: 471.223017073
Chemical FormulaC22H29N7O5
InChI KeyRXWNCPJZOCPEPQ-NVWDDTSBSA-N
InChI
InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
IUPAC Name
(2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)-9H-purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
SMILES
[H][C@](N)(CC1=CC=C(OC)C=C1)C(=O)N[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(N2C=NC3=C(N=CN=C23)N(C)C)[C@]1([H])O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
60S ribosomal protein L10-likeProteinunknownNot AvailableHumanQ96L21 details
60S ribosomal protein L13aProteinunknownNot AvailableHumanP40429 details
60S ribosomal protein L23ProteinunknownNot AvailableHumanP62829 details
60S ribosomal protein L15ProteinunknownNot AvailableHumanP61313 details
60S ribosomal protein L19ProteinunknownNot AvailableHumanP84098 details
60S ribosomal protein L23aProteinunknownNot AvailableHumanP62750 details
Probable ribosome biogenesis protein RLP24ProteinunknownNot AvailableHumanQ9UHA3 details
60S ribosomal protein L26-like 1ProteinunknownNot AvailableHumanQ9UNX3 details
60S ribosomal protein L8ProteinunknownNot AvailableHumanP62917 details
60S ribosomal protein L37ProteinunknownNot AvailableHumanP61927 details
60S ribosomal protein L3ProteinunknownNot AvailableHumanP39023 details
60S ribosomal protein L11ProteinunknownNot AvailableHumanP62913 details
Leucyl/phenylalanyl-tRNA--protein transferaseProteinunknownNot AvailableEscherichia coli (strain K12)P0A8P1 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Puromycin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Alendronic acidPuromycin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Puromycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Puromycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Puromycin.Approved, Investigational
AmpicillinThe serum concentration of Puromycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideHMPL-004 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
ApocyninAcetovanillone may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Atracurium besylatePuromycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Puromycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Puromycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Puromycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Puromycin.Approved, Investigational
Botulinum Toxin Type APuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Puromycin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Puromycin.Approved
CarbenicillinThe serum concentration of Puromycin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinPuromycin may increase the ototoxic activities of Carboplatin.Approved
CarprofenCarprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Cisatracurium besylatePuromycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Puromycin.Approved
Clodronic AcidPuromycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethatePuromycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Puromycin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Puromycin.Approved, Investigational
CyclosporinePuromycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DecamethoniumPuromycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Puromycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Puromycin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Puromycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.Approved, Investigational
Domoic AcidPuromycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chloridePuromycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
E-6201E6201 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Etidronic acidPuromycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
FenbufenFenbufen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Flucloxacillin.Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Puromycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Puromycin.Approved, Vet Approved
Gallamine TriethiodidePuromycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
IbandronatePuromycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Puromycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MecamylaminePuromycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Puromycin can be decreased when it is combined with Meticillin.Approved
MetocurinePuromycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodidePuromycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Puromycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumPuromycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Puromycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
NeosaxitoxinPuromycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Puromycin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OuabainOuabain may decrease the cardiotoxic activities of Puromycin.Approved
OxacillinThe serum concentration of Puromycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.Approved, Vet Approved
PamidronatePuromycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumPuromycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PipecuroniumPuromycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Puromycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Puromycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Puromycin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
RapacuroniumPuromycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental, Investigational
RisedronatePuromycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumPuromycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SRT501SRT501 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
SuccinylcholinePuromycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Puromycin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Puromycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Puromycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m medronatePuromycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
Tenofovir disoproxilThe serum concentration of Puromycin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Puromycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidPuromycin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.Approved
TranilastTranilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Puromycin.Approved, Investigational
TubocurarinePuromycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Puromycin.Approved
VecuroniumPuromycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidPuromycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)168°C-182°Chttp://www.fermentek.co.il/puromycin.htm
water solubility50mg/mlhttp://www.fermentek.co.il/puromycin.htm
Predicted Properties
PropertyValueSource
Water Solubility1.01 mg/mLALOGPS
logP-0.1ALOGPS
logP-0.3ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)12.35ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area160.88 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity122.96 m3·mol-1ChemAxon
Polarizability49.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier-0.8691
Caco-2 permeable-0.7728
P-glycoprotein substrateSubstrate0.737
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9243
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.7097
CYP450 1A2 substrateNon-inhibitor0.9058
CYP450 2C9 inhibitorNon-inhibitor0.9133
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9393
CYP450 3A4 inhibitorNon-inhibitor0.724
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8922
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8681
BiodegradationNot ready biodegradable0.9882
Rat acute toxicity2.2651 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9903
hERG inhibition (predictor II)Non-inhibitor0.5719
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-00di-0000900000-f82e7526c7ebd78049d9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-03k9-0900500000-0d48aed0c9497b5ab8f3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-03di-0900000000-af8be24075f803a58153View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-03di-0900000000-571b6483dc540c02d098View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-03di-0900000000-08775f201fb11e558b53View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-00di-0000900000-6133e2c60106f3437756View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-05fr-0005900000-a760a4943250cd5405b9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0a4i-0809000000-eb619283ee6c689551e3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0w29-0900000000-ca39c6d95b7bd8fba81bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , positivesplash10-0udi-0900000000-253fadebaa39d03e1cd1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0a4i-0219000000-6595a051c26ce2ee007bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-03di-0900300000-347a5da10b8c2c85e6c0View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-03dj-0900000000-4a2ce92d6902f4ad8eaaView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-03dj-1900000000-039465e4b89c78bd0b11View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0229-0520900000-37dea53aac093ce884f6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-03di-0910100000-f60802f57acd3074b4c1View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-03xs-1900000000-d2fbe55b0731a8cf001fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPurine nucleosides
Sub ClassPurine 3'-deoxyribonucleosides
Direct ParentPurine 3'-deoxyribonucleosides
Alternative ParentsPhenylalanine and derivatives / Alpha amino acid amides / 6-alkylaminopurines / Glycosylamines / Pentoses / Amphetamines and derivatives / Phenoxy compounds / Anisoles / Dialkylarylamines / Methoxybenzenes
SubstituentsPurine 3'-deoxyribonucleoside / Phenylalanine or derivatives / Alpha-amino acid amide / N-glycosyl compound / Glycosyl compound / 6-alkylaminopurine / 6-aminopurine / Alpha-amino acid or derivatives / Pentose monosaccharide / Amphetamine or derivatives
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorspuromycins (CHEBI:17939 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
May play a role in compensating for the inactivated X-linked gene during spermatogenesis.
Gene Name:
RPL10L
Uniprot ID:
Q96L21
Molecular Weight:
24518.595 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Associated with ribosomes but is not required for canonical ribosome function and has extra-ribosomal functions. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma activation and subsequent phosphorylation dissociates from the ribo...
Gene Name:
RPL13A
Uniprot ID:
P40429
Molecular Weight:
23577.11 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL23
Uniprot ID:
P62829
Molecular Weight:
14865.335 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL15
Uniprot ID:
P61313
Molecular Weight:
24145.945 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL19
Uniprot ID:
P84098
Molecular Weight:
23465.775 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
This protein binds to a specific region on the 26S rRNA.
Gene Name:
RPL23A
Uniprot ID:
P62750
Molecular Weight:
17694.885 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Involved in the biogenesis of the 60S ribosomal subunit. Ensures the docking of GTPBP4/NOG1 to pre-60S particles (By similarity).
Gene Name:
RSL24D1
Uniprot ID:
Q9UHA3
Molecular Weight:
19621.02 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL26L1
Uniprot ID:
Q9UNX3
Molecular Weight:
17256.2 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL8
Uniprot ID:
P62917
Molecular Weight:
28024.52 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Binds to the 23S rRNA.
Gene Name:
RPL37
Uniprot ID:
P61927
Molecular Weight:
11077.81 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
The L3 protein is a component of the large subunit of cytoplasmic ribosomes.
Gene Name:
RPL3
Uniprot ID:
P39023
Molecular Weight:
46108.72 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Binds to 5S ribosomal RNA (By similarity). Required for rRNA maturation and formation of the 60S ribosomal subunits. Promotes nucleolar location of PML (By similarity).
Gene Name:
RPL11
Uniprot ID:
P62913
Molecular Weight:
20252.235 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Transferase activity, transferring amino-acyl groups
Specific Function:
Functions in the N-end rule pathway of protein degradation where it conjugates Leu, Phe and, less efficiently, Met from aminoacyl-tRNAs to the N-termini of proteins containing an N-terminal arginine or lysine.
Gene Name:
aat
Uniprot ID:
P0A8P1
Molecular Weight:
26618.275 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:31 / Updated on June 24, 2017 13:28